NCT01022762
- Conditions
- Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
- Locations
-
- Shanghai, Shanghai Municipality, China
Clinical trial condition
Diabetes Mellitus, Type 2
Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.
2,679 public trials
158 recruiting studies
Diabetes Mellitus, Type 2 trial results
NCT02183350
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
Not specified
NCT00309608
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.6.3302A Boehringer Ingelheim Investigational Site Joué Les Tours, France
- 1218.6.3303A Boehringer Ingelheim Investigational Site Joué Les Tours, France
- 1218.6.3304A Boehringer Ingelheim Investigational Site Joué-lès-Tours, France
- 1218.6.3305A Euraxi Pharma Joué-lès-Tours, France
NCT02183415
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
Not specified
NCT01924767
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1245.2.1 Boehringer Ingelheim Investigational Site Neuss, Germany
NCT00108225
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- VA Medical Center, Minneapolis Minneapolis, Minnesota, United States
NCT01087502
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.64.10007 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
- 1218.64.10018 Boehringer Ingelheim Investigational Site Pembroke Pines, Florida, United States
- 1218.64.10016 Boehringer Ingelheim Investigational Site Decatur, Georgia, United States
- 1218.64.10015 Boehringer Ingelheim Investigational Site Boise, Idaho, United States
Completed
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
NCT00736099
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.40.10003 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
- 1218.40.10014 Boehringer Ingelheim Investigational Site Spring Valley, California, United States
- 1218.40.10001 Boehringer Ingelheim Investigational Site Walnut Creek, California, United States
- 1218.40.10021 Boehringer Ingelheim Investigational Site Northglenn, Colorado, United States
NCT00819091
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.35.10002 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
- 1218.35.10001 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
- 1218.35.10016 Boehringer Ingelheim Investigational Site National City, California, United States
- 1218.35.10017 Boehringer Ingelheim Investigational Site Fort Lauderdale, Florida, United States
NCT01012037
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.62.32003 Boehringer Ingelheim Investigational Site De Pinte, Belgium
- 1218.62.32008 Boehringer Ingelheim Investigational Site Kortenaken, Belgium
- 1218.62.32009 Boehringer Ingelheim Investigational Site Kumtich, Belgium
- 1218.62.32005 Boehringer Ingelheim Investigational Site Massemen-Wetteren, Belgium